Biological serum markers in the management of pediatric pulmonary arterial hypertension (Q46743475)

24 December 2017

title

Biological serum markers in the management of pediatric pulmonary arterial hypertension (English)

1 reference

24 December 2017

main subject

arterial hypertension

0 references

author name string

Mirjam E Van Albada

1

1 reference

24 December 2017

Frederieke G Loot

2

1 reference

24 December 2017

Rebecca Fokkema

3

1 reference

24 December 2017

Marcus T R Roofthooft

4

1 reference

24 December 2017

Rolf M F Berger

5

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

24 December 2017

published in

Pediatric Research

1 reference

24 December 2017

volume

63

1 reference

24 December 2017

page(s)

321-327

1 reference

24 December 2017

issue

3

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1203/pdr.0b013e318163a2e7

exact match

0 references

cites work

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Pulmonary plasma catecholamine levels and pulmonary hypertension in congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

B-type natriuretic peptide in pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Plasma norepinephrine in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Prognostic and therapeutic considerations in clinical primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Survival in primary pulmonary hypertension. Validation of a prognostic equation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Hyperuricemia as a prognostic factor in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

Hyperuricaemia in patients with right or left heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318163A2E7

10.1203/PDR.0B013E318163A2E7

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

Dimensions Publication ID

0 references

1 reference

24 December 2017